PartnershipAug 3, 2026, 07:07 AM
Genprex Partners with Roche Diagnostics for NSCLC Biomarker Validation
AI Summary
Genprex, Inc. announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer (NSCLC) clinical trials. This partnership builds on promising preclinical and clinical data indicating that TROP2 and PTEN H-scores can predict patient response and progression-free survival. Leveraging Roche Diagnostics' expertise and FDA Breakthrough Device Designation for a TROP2 diagnostic, Genprex aims to refine patient identification and integrate these biomarkers into its NSCLC clinical program by the end of 2026, ultimately delivering more effective, personalized treatment options.
Key Highlights
- Genprex announced collaboration with Roche Diagnostics for biomarker validation.
- The partnership focuses on TROP2 and PTEN biomarkers for non-small cell lung cancer (NSCLC).
- Preclinical and clinical data showed high TROP2 and low PTEN H-scores predicted patient response and longer Progression Free Survival.
- Roche Diagnostics has FDA Breakthrough Device Designation for an AI-driven TROP2 diagnostic.
- Genprex will use the same TROP2 antibody as Roche for consistency in validation studies.
- Validation studies are anticipated to be completed by approximately the end of 2026.
- The collaboration aims to shorten patient identification and recruitment time for NSCLC clinical trials.
Price Impact
More from GNPX